RecruitingType 2 Diabetes Mellitus

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin

Eligible age

18+ yrs

Accepts

All genders

Locations

12 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron compared with placebo in adults with Type 2 Diabetes Mellitus (T2DM), treated with a background insulin and other background glucose-lowering medication(s)

Sponsor: AstraZeneca

You may qualify if…

✓ Diagnosed with T2DM for at least 90 days prior to screening
✓ Stable treatment with background insulin and other background glucose-lowering medication(s)
✓ HbA1c value of ≥ 7% to ≤ 10.5%
✓ Body mass index (BMI) of ≥ 23 kg/m2 at screening
✓ Stable body weight (self-reported or documented) for 90 days prior to screening

You may not qualify if…

✕ T1DM, secondary forms of diabetes (including congenital forms), or history of ketoacidosis or hyperosmolar coma
✕ Currently receiving or anticipated to receive, therapeutic intervention for diabetic retinopathy and/or macular edema
✕ Have had more than one episode of severe hypoglycemia within 180 days prior to screening or has a history of hypoglycemia unawareness or poor recognition of hypoglycemic symptoms
✕ Clinically significant condition affecting the upper GI tract or chronic use of any medication that affects gastric motility or gastric emptying
✕ History of acute or chronic pancreatitis.
✕ Severe congestive heart failure (NYHA IV)
✕ History/family history of medullary thyroid cancer or multiple endocrine neoplasia type 2